Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP‐lesioned marmosets: Mediation by D2, not D3, dopamine receptors
Identifieur interne : 003589 ( Main/Exploration ); précédent : 003588; suivant : 003590Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP‐lesioned marmosets: Mediation by D2, not D3, dopamine receptors
Auteurs : Michael P. Hill [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni] ; Steven G. Mcguire [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni, Canada] ; Alan R. Crossman [Royaume-Uni] ; Catherine Rochat [France] ; Mark J. Millan [France]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-12.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Analysis of Variance, Animals, Antiparkinson Agents (therapeutic use), Behavior, Animal (drug effects), Callithrix, D2 Dopamine receptor, D2/D3 receptors, D3 Dopamine receptor, Disease Models, Animal, Dopamine Antagonists (therapeutic use), Dose-Response Relationship, Drug, Drug Administration Schedule, Dyskinesia, Indoles (therapeutic use), Levodopa, Levodopa (therapeutic use), L‐dopa, MPTP, MPTP Poisoning (drug therapy), MPTP Poisoning (physiopathology), Motor Activity (drug effects), Nervous system diseases, Oxazines (therapeutic use), Parkinson disease, Parkinson's disease, Piperidines (therapeutic use), Receptors, Dopamine D2 (physiology), Receptors, Dopamine D3 (physiology), Time Factors, dyskinesia.
- MESH :
- chemical , physiology : Receptors, Dopamine D2, Receptors, Dopamine D3.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Antagonists, Indoles, Levodopa, Oxazines, Piperidines.
- drug effects : Behavior, Animal, Motor Activity.
- drug therapy : MPTP Poisoning.
- physiopathology : MPTP Poisoning.
- Analysis of Variance, Animals, Callithrix, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Administration Schedule, Time Factors.
Abstract
L‐dopa remains the most common treatment for Parkinson's disease. However, there is considerable interest in D3/D2 receptor agonists such as the novel agent S32504, since they exert antiparkinsonian properties in the absence of dyskinesia. An important question concerns the roles of D2 vs. D3 receptors, an issue we addressed with the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)–lesioned nonhuman primate model of Parkinson's disease. In L‐dopa–primed animals, S32504 (0.16–2.5 mg/kg p.o.) dose‐dependently enhanced locomotor activity. This action was abolished by the D2 antagonist, L741,626 (2.5 mg/kg), but potentiated by the D3 antagonist, S33084 (0.63 mg/kg). Both antagonists were inactive alone. In drug‐naive animals, a maximally effective dose of S32504 (2.5 mg/kg p.o.) displayed pronounced antiparkinsonian properties from the third day of administration, and its actions were expressed rapidly and durably. Thus, on day 33, antiparkinsonian properties of S32504 were apparent within 5 minutes and present for > 4 hours. Moreover, they were associated with neither wearing off nor significant dyskinesia. In conclusion, the novel D3/D2 agonist S32504 may offer advantages over L‐dopa in the treatment of newly diagnosed parkinsonian patients. Its actions are expressed primarily by activation of D2, not D3, receptors. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21106
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002708
- to stream Istex, to step Curation: 002708
- to stream Istex, to step Checkpoint: 002050
- to stream PubMed, to step Corpus: 002A82
- to stream PubMed, to step Curation: 002A82
- to stream PubMed, to step Checkpoint: 002E78
- to stream Ncbi, to step Merge: 001857
- to stream Ncbi, to step Curation: 001857
- to stream Ncbi, to step Checkpoint: 001857
- to stream Main, to step Merge: 004904
- to stream PascalFrancis, to step Corpus: 001881
- to stream PascalFrancis, to step Curation: 001440
- to stream PascalFrancis, to step Checkpoint: 001C35
- to stream Main, to step Merge: 004D30
- to stream Main, to step Curation: 003589
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP‐lesioned marmosets: Mediation by D2, not D3, dopamine receptors</title><author><name sortKey="Hill, Michael P" sort="Hill, Michael P" uniqKey="Hill M" first="Michael P." last="Hill">Michael P. Hill</name></author><author><name sortKey="Ravenscroft, Paula" sort="Ravenscroft, Paula" uniqKey="Ravenscroft P" first="Paula" last="Ravenscroft">Paula Ravenscroft</name></author><author><name sortKey="Mcguire, Steven G" sort="Mcguire, Steven G" uniqKey="Mcguire S" first="Steven G." last="Mcguire">Steven G. Mcguire</name></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name></author><author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name></author><author><name sortKey="Rochat, Catherine" sort="Rochat, Catherine" uniqKey="Rochat C" first="Catherine" last="Rochat">Catherine Rochat</name></author><author><name sortKey="Millan, Mark J" sort="Millan, Mark J" uniqKey="Millan M" first="Mark J." last="Millan">Mark J. Millan</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B6387AB6610DDCB65CB35C3994A0D3A9C708BEE9</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.21106</idno><idno type="url">https://api.istex.fr/document/B6387AB6610DDCB65CB35C3994A0D3A9C708BEE9/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002708</idno><idno type="wicri:Area/Istex/Curation">002708</idno><idno type="wicri:Area/Istex/Checkpoint">002050</idno><idno type="wicri:doubleKey">0885-3185:2006:Hill M:antiparkinsonian:effects:of</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16991143</idno><idno type="wicri:Area/PubMed/Corpus">002A82</idno><idno type="wicri:Area/PubMed/Curation">002A82</idno><idno type="wicri:Area/PubMed/Checkpoint">002E78</idno><idno type="wicri:Area/Ncbi/Merge">001857</idno><idno type="wicri:Area/Ncbi/Curation">001857</idno><idno type="wicri:Area/Ncbi/Checkpoint">001857</idno><idno type="wicri:doubleKey">0885-3185:2006:Hill M:antiparkinsonian:effects:of</idno><idno type="wicri:Area/Main/Merge">004904</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:07-0090858</idno><idno type="wicri:Area/PascalFrancis/Corpus">001881</idno><idno type="wicri:Area/PascalFrancis/Curation">001440</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001C35</idno><idno type="wicri:doubleKey">0885-3185:2006:Hill M:antiparkinsonian:effects:of</idno><idno type="wicri:Area/Main/Merge">004D30</idno><idno type="wicri:Area/Main/Curation">003589</idno><idno type="wicri:Area/Main/Exploration">003589</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP‐lesioned marmosets: Mediation by D2, not D3, dopamine receptors</title><author><name sortKey="Hill, Michael P" sort="Hill, Michael P" uniqKey="Hill M" first="Michael P." last="Hill">Michael P. Hill</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience, Ltd., Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Ravenscroft, Paula" sort="Ravenscroft, Paula" uniqKey="Ravenscroft P" first="Paula" last="Ravenscroft">Paula Ravenscroft</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience, Ltd., Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Mcguire, Steven G" sort="Mcguire, Steven G" uniqKey="Mcguire S" first="Steven G." last="Mcguire">Steven G. Mcguire</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience, Ltd., Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience, Ltd., Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Current Address: Toronto Western Research Institute, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience, Ltd., Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>School of Biological Sciences, University of Manchester, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName><orgName type="university">Université de Manchester</orgName></affiliation></author><author><name sortKey="Rochat, Catherine" sort="Rochat, Catherine" uniqKey="Rochat C" first="Catherine" last="Rochat">Catherine Rochat</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>IDR Servier, Croissy‐sur‐Seine</wicri:regionArea><wicri:noRegion>Croissy‐sur‐Seine</wicri:noRegion><wicri:noRegion>Croissy‐sur‐Seine</wicri:noRegion></affiliation></author><author><name sortKey="Millan, Mark J" sort="Millan, Mark J" uniqKey="Millan M" first="Mark J." last="Millan">Mark J. Millan</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>IDR Servier, Croissy‐sur‐Seine</wicri:regionArea><wicri:noRegion>Croissy‐sur‐Seine</wicri:noRegion><wicri:noRegion>Croissy‐sur‐Seine</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-12">2006-12</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="2090">2090</biblScope><biblScope unit="page" to="2095">2095</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">B6387AB6610DDCB65CB35C3994A0D3A9C708BEE9</idno><idno type="DOI">10.1002/mds.21106</idno><idno type="ArticleID">MDS21106</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analysis of Variance</term><term>Animals</term><term>Antiparkinson Agents (therapeutic use)</term><term>Behavior, Animal (drug effects)</term><term>Callithrix</term><term>D2 Dopamine receptor</term><term>D2/D3 receptors</term><term>D3 Dopamine receptor</term><term>Disease Models, Animal</term><term>Dopamine Antagonists (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Dyskinesia</term><term>Indoles (therapeutic use)</term><term>Levodopa</term><term>Levodopa (therapeutic use)</term><term>L‐dopa</term><term>MPTP</term><term>MPTP Poisoning (drug therapy)</term><term>MPTP Poisoning (physiopathology)</term><term>Motor Activity (drug effects)</term><term>Nervous system diseases</term><term>Oxazines (therapeutic use)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Piperidines (therapeutic use)</term><term>Receptors, Dopamine D2 (physiology)</term><term>Receptors, Dopamine D3 (physiology)</term><term>Time Factors</term><term>dyskinesia</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Receptors, Dopamine D2</term><term>Receptors, Dopamine D3</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Antagonists</term><term>Indoles</term><term>Levodopa</term><term>Oxazines</term><term>Piperidines</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior, Animal</term><term>Motor Activity</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>MPTP Poisoning</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>MPTP Poisoning</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term><term>Animals</term><term>Callithrix</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Time Factors</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term><term>Lévodopa</term><term>Parkinson maladie</term><term>Récepteur dopaminergique D2</term><term>Récepteur dopaminergique D3</term><term>Système nerveux pathologie</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">L‐dopa remains the most common treatment for Parkinson's disease. However, there is considerable interest in D3/D2 receptor agonists such as the novel agent S32504, since they exert antiparkinsonian properties in the absence of dyskinesia. An important question concerns the roles of D2 vs. D3 receptors, an issue we addressed with the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)–lesioned nonhuman primate model of Parkinson's disease. In L‐dopa–primed animals, S32504 (0.16–2.5 mg/kg p.o.) dose‐dependently enhanced locomotor activity. This action was abolished by the D2 antagonist, L741,626 (2.5 mg/kg), but potentiated by the D3 antagonist, S33084 (0.63 mg/kg). Both antagonists were inactive alone. In drug‐naive animals, a maximally effective dose of S32504 (2.5 mg/kg p.o.) displayed pronounced antiparkinsonian properties from the third day of administration, and its actions were expressed rapidly and durably. Thus, on day 33, antiparkinsonian properties of S32504 were apparent within 5 minutes and present for > 4 hours. Moreover, they were associated with neither wearing off nor significant dyskinesia. In conclusion, the novel D3/D2 agonist S32504 may offer advantages over L‐dopa in the treatment of newly diagnosed parkinsonian patients. Its actions are expressed primarily by activation of D2, not D3, receptors. © 2006 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Canada</li><li>France</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Manchester</li></region><settlement><li>Manchester</li></settlement><orgName><li>Université de Manchester</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Hill, Michael P" sort="Hill, Michael P" uniqKey="Hill M" first="Michael P." last="Hill">Michael P. Hill</name></region><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name><name sortKey="Mcguire, Steven G" sort="Mcguire, Steven G" uniqKey="Mcguire S" first="Steven G." last="Mcguire">Steven G. Mcguire</name><name sortKey="Ravenscroft, Paula" sort="Ravenscroft, Paula" uniqKey="Ravenscroft P" first="Paula" last="Ravenscroft">Paula Ravenscroft</name></country><country name="Canada"><noRegion><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name></noRegion></country><country name="France"><noRegion><name sortKey="Rochat, Catherine" sort="Rochat, Catherine" uniqKey="Rochat C" first="Catherine" last="Rochat">Catherine Rochat</name></noRegion><name sortKey="Millan, Mark J" sort="Millan, Mark J" uniqKey="Millan M" first="Mark J." last="Millan">Mark J. Millan</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003589 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003589 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:B6387AB6610DDCB65CB35C3994A0D3A9C708BEE9
|texte= Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP‐lesioned marmosets: Mediation by D2, not D3, dopamine receptors
}}
| This area was generated with Dilib version V0.6.23. |  |